

# Update Adipositas-Therapie: Neue Medikamente und bariatrische Chirurgie auf dem Prüfstand

J. Hoyer, M. Dressler, T. Lohmann

## Literatur

- [1] Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *NEJM* 2009, 360: 859-873
- [2] Bischoff SC, Damm-Machado A, Betz C, Herpertz S, Legenbauer T, Löw T, Wechsler JG, Bischoff G, Austel A, Ellrott T. Multicenter evaluation of an interdisciplinary 52-week weight loss programme for obesity with regard to body weight, comorbidities and quality of life - a prospective study. *Int J Obes* 2012, 36: 614-624.
- [3] Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Moller KN, Blond MB, Jensen J-EB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Healthy weight loss maintenance with exercise, liraglutide, or both combined. *N Engl J Med* 2021, 384: 1719-1730
- [4] Berg A, Frey I, Hamm M, Fuchs R, Göhner W, Lagerstrom D, Predel H-G, Berg A. Das MOBILIS-Programm. *Adipositas* 2008, 2: 90-95.
- [5] Renjilian DA, Perri MG, Nezu AM, McKelvey WF, Shermer RL, Anton SD. Individual versus group therapy for obesity: Effects of matching participants to their treatment preferences. *Journal of Consulting and Clinical Psychology* 2001, 69: 717-721.
- [6] Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters K, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 2018; 391: 541-551.
- [7] Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters K, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diab Endocrinol* 2019, 7:344-355.
- [8] Sjostrom L, Lindroos A, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors in 10 years after bariatric surgery. *NEJM* 2004
- [9] Arterburn DE, Olsen MK, Smith VA, Livingston EH, van Scoyoc L, Jancy WS, Eid G, Weidenbacher H, Maciejewski ML. Association between bariatric surgery and mortality. *JAMA* 2015, 313: 62-70.

- [10] Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ, O'Brien R, Bogart A, Theis MK, Anau J, Schroeder MB, Sidney S. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. *JAMA* 2018, 320: 1570-1582.
- [11] Sjöholm K, Carlsson LMS, Svensson P-A, Andersson-Assersson JC, Kristensson F, Jacobson P, Peltonen M, Taube M. Association of bariatric surgery with cancer incidence in patients with obesity and diabetes: long-term results from the Swedish obese subjects study. *Diab Care* 45: 444-455.
- [12] Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O'Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J. A multisite study of long-term remission and relapse of type 2 diabetes following gastric bypass. *Obes Surg* 2013, 23: 93-102.
- [13] Miras AD, Perez-Pevida D, Aldhwayan M, Kamocka A, McGlone MR, Al-Najim W, Chahal H, Batterham RL, McGowan B, Khan O, Greener V, Ahmed AR, Petrie A, Scholtz S, Bloom SR, Tan TM. Adjunctive liraglutide treatment in patients with persistent or recurrent diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. *Lancet Diab Endocrinol* 2019, 7: 549-559.
- [14] Mingrone B, Panunzi S, de Gaetano A, Guidone C, Iaiconelli A, Capristo E, Ghamseddine C, Bornstein SR, Rubino F. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet* 2021, 397: 293-304.
- [15] Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D, Millat B, Fagot-Campagna A. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. *Lancet Diab Endocrinol* 2019, 7: 786-795.
- [16] Rosseau C, Jean S, Gamache P, Lebel S, Mac-Way F, BIRTHO L, Michou L, Gagnon C. Change in fracture risk and fracture pattern after bariatric surgery: A nested case-control study. *BMJ* 2021, 374: 13794.
- [17] Coen PM, Tanner CJ, Helbling NL, Dubis GS, Hames KC, Xie H, Eid GM, Stefanovic-Racic M, Toledo FGS, Jakicic JM, Houmard JA, Goodpaster GH. Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. *J Clin Invest* 2015, 125:248-257.
- [18] Neovius M, Bruze G, Jacobson P, Sjöholm K, Johansson K, Granath F, Sundström J, Näslund I, Marcus C, Ottoson J, Peltonen M, Carlsson LMS. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. *Lancet Diabet Endocrinol* 2018, 6: 197-207.
- [19] Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, for the COR-II study group. A randomized phase 3 trial of Naltrexone SR/Bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity* 2013, 21: 935-943.
- [20] O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet* 2018, 392: 637-649.
- [21] Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Lando LF, Bergman BK, Liu B, Cui X, Brown K, for the SURPASS-2 investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *New Engl J Med* 2021, 385: 503-515.